Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | SVP, Reg.& Precision Medicine | December 14, 2016 | December 15, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date December 14, 2016 · Filed December 15, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-12-14 | Direct | 75,000 |
Reported balance
After 2016-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-14 · Grant · Acquired 75,000 · Balance 75,000 F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2: 25% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
F2: 25% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2016 Filed Dec 15, 2016 21:08 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001179110-16-033001 · edgar.xml · derivative · entry 1 LaVallee Theresa · CIK 0001690948 · SVP, Reg.& Precision Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-12-14 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.